Amy Schell, MD
Hematology & Oncology · Lexington, KYNPI 1437265436
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,665 of the $2,205 with a category attached, or 75.5%. AstraZeneca accounts for 84.9% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2021 at $1,827 and has fallen 96.2% since, to $70 in 2025. That places this record below the midpoint for hematology & oncology clinicians in KY, where the typical reported total is $4,619.
Across 16 payments — averaging $137.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Galvanize Therapeutics, Inc$113
- Channel Medsystems, Inc.$38
- Iovance Biotherapeutics, Inc.$34
- Pfizer$33
- Tosoh Bioscience, Inc.$25
- plus $91 from 5 others
Across 121 payments — averaging $4574.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$343K
- Tolmar, Inc.$150K
- Genentech, Inc.$50K
- Astrazeneca UK Limited$11K
- Merck$257
What the payments were for
- Consulting fees$1,66576%
- Speaking & faculty fees$1507%
- Food & beverage$31414%
- Education$502%
- Gifts$251%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 4 | $1,871 |
| Galvanize Therapeutics, Inc | 1 | $113 |
| Channel Medsystems, Inc. | 1 | $38 |
| Iovance Biotherapeutics, Inc. | 1 | $34 |
| Pfizer | 2 | $33 |
| Tosoh Bioscience, Inc. | 1 | $25 |
| Gilead | 2 | $24 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Array Biopharma Inc | 1 | $22 |
| Novo Nordisk | 1 | $14 |
| Merck | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIRIS$150
- ALIYA SYSTEM$113
How this compares
$2,205 in reported general payments places this provider in the 30th percentile of 143 hematology & oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 58 | $1,142,377 |
| CalquenceAcalabrutinib Maleate | 41 | $595,343 |
| Lenalidomide | 46 | $566,896 |
| OrserduElacestrant Hcl | 21 | $485,343 |
| KisqaliRibociclib Succinate | 26 | $417,521 |
| IbrancePalbociclib | 21 | $337,311 |
| LorbrenaLorlatinib | 12 | $297,642 |
| BosulifBosutinib | 13 | $240,917 |
| VerzenioAbemaciclib | 15 | $230,368 |
| ImbruvicaIbrutinib | 15 | $228,794 |
| Imatinib Mesylate | 16 | $64,130 |
| EliquisApixaban | 53 | $35,523 |
| VeozahFezolinetant | 22 | $11,878 |
| Exemestane | 55 | $11,098 |
| Anastrozole | 749 | $9,126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Lorbrena, Bosulif, Eliquis | $33 | $911,39299 claims |
| AstraZenecaCalquence | $1,871 | $595,34341 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 143 hematology & oncology providers in Kentucky.
Other hematology & oncology in Lexington
- Firas BadinLexington$1.6M
- Nicola JabbourLexington$563K
- John VillanoLexington$16K
- Christopher BurkeenLexington$13K
- Jessica CroleyLexington$12K
- Roger FleischmanLexington$12K
- Ayman QasrawiLexington$9K
- Ryan WoodsLexington$6K
- Vivek SharmaLouisville$647K
- Goetz KloeckerLouisville$584K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.